Inhibikase Therapeutics Inc. Common Stock (IKT)
Stock · NASDAQ · Health Care
$2.42as of 8/28/2026
Price chart
Open in TradingViewActive signals
About IKT
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate design…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 35
- Website
- www.inhibikase.com
Fundamentals
- 1-day range
- $2.37$2.44
- Market cap
- $318.20M
- P/E (trailing)
- —
- P/E (forward)
- -5.57
- EPS (trailing)
- $-0.44
- Dividend yield
- —
- Beta
- 0.95
- Avg. volume
- 836.9K
How Inhibikase Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 31, 2023 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Inhibikase Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IKTInhibikase Therapeutics Inc. Common Stock$2.42▼ 2.23%Market cap $318.20MP/E —$1.33$2.53
- AVXLAnavex Life Sciences Corp. Common Stock$2.98▼ 4.79%Market cap $303.96MP/E —$2.26$10.4
- NMRANeumora Therapeutics Inc. Common Stock$1.38▼ 6.76%Market cap $303.87MP/E —$0.83015$3.65
- AGENAgenus Inc. Common Stock$7.67▼ 1.79%Market cap $335.19MP/E 4.88$2.71$8.85
- SABSSAB Biotherapeutics Inc. Common Stock$3.79▼ 3.56%Market cap $294.39MP/E 26.94$1.85$5.15
- IPSCCentury Therapeutics Inc. Common Stock$2.03▼ 9.19%Market cap $342.67MP/E —$0.435$3.04
- FATEFate Therapeutics Inc. Common Stock$2.42▼ 4.92%Market cap $290.23MP/E —
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics Inc. Common Stock | $318.20M | — | $2.42 | ▼ 2.23% | $1.33$2.53 |
| AVXL Anavex Life Sciences Corp. Common Stock | $303.96M | — | $2.98 | ▼ 4.79% | $2.26$10.4 |
| NMRA Neumora Therapeutics Inc. Common Stock | $303.87M | — | $1.38 | ▼ 6.76% | $0.83015$3.65 |
| AGEN Agenus Inc. Common Stock | $335.19M | 4.88 | $7.67 | ▼ 1.79% | $2.71$8.85 |
| SABS SAB Biotherapeutics Inc. Common Stock | $294.39M | 26.94 | $3.79 | ▼ 3.56% | $1.85$5.15 |
| IPSC Century Therapeutics Inc. Common Stock | $342.67M | — | $2.03 | ▼ 9.19% | $0.435$3.04 |
| FATE Fate Therapeutics Inc. Common Stock | $290.23M | — | $2.42 | ▼ 4.92% |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Inhibikase Therapeutics Q2 EPS $(0.11), Inlinebenzinga · 8/11/2026
- Inhibikase Therapeutics Q2 EPS $(0.11), InlineBenzinga · 8/11/2026
Insider Activity
Insider Actions →- Dennis N. Berman · July 30, 2026 · Option Exercise21.9K @ $1.26
- RA CAPITAL MANAGEMENT, L.P. · July 29, 2026 · J18.03M
Institutional Ownership
March 31, 2026
- Total shares held
- 112.45M
- Total value held
- $188.53M
- Institutional holders
- 100
- Unknown13.02M
- Unknown10.88M
- Unknown8.63M
- Unknown8.06M
- Unknown6.61M
- Unknown6.30M
- Unknown5.94M
- Unknown5.85M
- Unknown5.40M
- Unknown4.45M
See the full, filterable feed with live charts on the MarketWall dashboard.